Judah Frommer

Stock Analyst at Morgan Stanley

(2.98)
# 497
Out of 5,370 analysts
193
Total ratings
60.80%
Success rate
36.73%
Average return
43 Stocks
Name Action PT Current % Upside Ratings Updated
BPMC Blueprint Medicines
Maintains: Equal-Weight
102 129
128.09 0.71% 2 Jun 5, 2025
CLDX Celldex Therapeutics
Maintains: Overweight
46 43
20.4 110.78% 2 May 9, 2025
ABVX Abivax
Assumes: Equal-Weight
12
6.76 77.51% 1 Mar 20, 2025
RGNX Regenxbio
Maintains: Overweight
22 24
9.14 162.58% 2 Mar 14, 2025
GLPG Galapagos
Downgrades: Underweight
31 22
28.82 -23.66% 3 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
8 6
4.38 36.99% 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
31
18.32 69.21% 1 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
81 106
64.14 65.26% 2 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
35
9.95 251.76% 1 Oct 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
2.46 428.46% 1 Apr 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Equal-Weight
3
0.98 206.12% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
40
5.62 611.74% 8 Aug 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
4
n/a n/a 3 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.14 1040.35% 5 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30
29.84 0.54% 8 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
23
11.7 96.58% 5 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
50
51.79 -3.46% 9 Jul 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
141
20.99 571.75% 13 Jun 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.42 815.49% 5 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
9
2.23 303.59% 5 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
175 138
n/a n/a 6 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
21 22
19.75 11.39% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
8 7
5.16 35.66% 3 Mar 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 1
n/a n/a 4 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
11 8
6.79 17.82% 5 Mar 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
14.62 214.64% 5 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
7 7
1.17 498.29% 6 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
51 55
15.11 264% 3 Feb 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
101.26 -54.57% 1 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
4 4
n/a n/a 1 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
14 10
n/a n/a 2 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
47 49
87.46 -43.97% 4 Nov 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
328 370
984.1 -62.4% 2 Oct 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 31
76.61 -59.54% 6 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 76
74.78 1.63% 8 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
182
113.69 60.08% 6 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
107
98.9 8.19% 13 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
90 95
120.8 -21.36% 10 Jul 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
18
21.55 -16.47% 1 Jul 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
93 116
126.28 -8.14% 12 Jun 10, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
31 38
108.89 -65.1% 4 May 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 22
160.38 -86.28% 1 May 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
33 35
66.03 -46.99% 9 Apr 29, 2020